CompletedNCT00790738
Liothyronine (T3) for depression in bipolarity
Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Glen OaksSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJuly 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 11
- Sponsor
- Northwell Health
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00790738
- Official title
Show the full official title
Randomized Double-Blind Trial of Liothyronine (T3) Augmentation to Treatment as Usual vs Placebo For The Treatment of Bipolar Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Glen Oaks
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Northwell Health.
Did this study involve medication?
Yes. The study involved medication, including Liothyronine (T3) and placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
